Literature DB >> 16890871

Rapid dilation of the abdominal aorta during infusion of angiotensin II detected by noninvasive high-frequency ultrasonography.

Chiara Barisione1, Richard Charnigo, Deborah A Howatt, Jessica J Moorleghen, Debra L Rateri, Alan Daugherty.   

Abstract

BACKGROUND: Infusion of angiotensin II (AngII) via subcutaneous osmotic pumps into mice promotes the development of abdominal aortic aneurysms (AAAs). These AngII-induced AAAs develop via a complex process in which there is a transmedial break, lumen dilation, thrombus formation, inflammation involving cells of both the innate and acquired immune systems, and remodeling. The recent development of a high-frequency ultrasound machine has permitted the noninvasive detection of murine abdominal aortas. We assessed the ability of a Visualsonics Vevo 660 high-resolution imaging system to detect AAAs and sequentially quantify the aortic luminal diameter. This system had 100% accuracy in detecting AngII-induced AAAs in vivo, with intrauser and interuser variation coefficients of less than 10% for quantification of the aortic lumen diameter.
METHODS: Male apolipoprotein E (apoE)(-/-) mice were infused subcutaneously with either saline or AngII and were monitored with this ultrasonic system to define the temporal changes in aortic lumen diameter. Aortic luminal diameters were measured in the aneurysm-susceptible region of the suprarenal aorta. For internal controls, abdominal aortic diameters were measured at the level of the left renal branch, because this landmark region did not dilate during AngII infusion.
RESULTS: Luminal diameters of the suprarenal aorta did not change significantly in saline-infused mice over 28 days of measurement (P = .71). In contrast, AngII infusion led to rapid dilation of suprarenal aortas during the initial 7 days of infusion (0.071 mm/d; P = .0037 for the change in the initial expansion rate). Further luminal diameter expansions occurred for the remaining 21 days of observation at a more modest rate (0.023 mm/d; P = .0001 for continued expansion after day 7). Within the initial 14 days of AngII infusion, some apoE(-/-) mice died as a result of rupture of the aorta in the suprarenal region. We had previously assumed that aortic dilation and rupture occurred simultaneously. However, in the AngII-infused mice that succumbed to aortic rupture, luminal diameters increased several days before death.
CONCLUSIONS: High-frequency ultrasonography demonstrated that suprarenal aortic expansion occurs rapidly after the initiation of AngII infusion into apoE(-/-) mice.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16890871     DOI: 10.1016/j.jvs.2006.04.047

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  62 in total

1.  Quantitative estimates of the variability of in vivo sonographic measurements of the mouse aorta for studies of abdominal aortic aneurysms and related arterial diseases.

Authors:  Uchechukwu K Sampson; Prudhvidhar R Perati; Petra A Prins; Wellington Pham; Zhouwen Liu; Frank E Harrell; MacRae F Linton; John C Gore; Valentina Kon; Sergio Fazio
Journal:  J Ultrasound Med       Date:  2011-06       Impact factor: 2.153

2.  Calpain inhibition attenuates angiotensin II-induced abdominal aortic aneurysms and atherosclerosis in low-density lipoprotein receptor-deficient mice.

Authors:  Venkateswaran Subramanian; Haruhito A Uchida; Talha Ijaz; Jessica J Moorleghen; Deborah A Howatt; Anju Balakrishnan
Journal:  J Cardiovasc Pharmacol       Date:  2012-01       Impact factor: 3.105

3.  Influences of aortic motion and curvature on vessel expansion in murine experimental aneurysms.

Authors:  Craig J Goergen; Junya Azuma; Kyla N Barr; Lars Magdefessel; Dara Y Kallop; Alvin Gogineni; Amarjeet Grewall; Robby M Weimer; Andrew J Connolly; Ronald L Dalman; Charles A Taylor; Philip S Tsao; Joan M Greve
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-11-11       Impact factor: 8.311

Review 4.  Lessons from Animal Models of Arterial Aneurysm.

Authors:  S David Gertz; Yoav Mintz; Ronen Beeri; Chen Rubinstein; Dan Gilon; Leah Gavish; Yacov Berlatzky; Liat Appelbaum; Lilach Gavish
Journal:  Aorta (Stamford)       Date:  2013-10-01

Review 5.  The role of the renin-angiotensin system in aortic aneurysmal diseases.

Authors:  Hong Lu; Debra L Rateri; Lisa A Cassis; Alan Daugherty
Journal:  Curr Hypertens Rep       Date:  2008-04       Impact factor: 5.369

6.  Hyperglycemia limits experimental aortic aneurysm progression.

Authors:  Noriyuki Miyama; Monica M Dua; Janice J Yeung; Geoffrey M Schultz; Tomoko Asagami; Eiketsu Sho; Mien Sho; Ronald L Dalman
Journal:  J Vasc Surg       Date:  2010-08-03       Impact factor: 4.268

7.  Castration of male mice prevents the progression of established angiotensin II-induced abdominal aortic aneurysms.

Authors:  Xuan Zhang; Sean Thatcher; Congqing Wu; Alan Daugherty; Lisa A Cassis
Journal:  J Vasc Surg       Date:  2014-01-16       Impact factor: 4.268

8.  Peptide inhibitor of CXCL4-CCL5 heterodimer formation, MKEY, inhibits experimental aortic aneurysm initiation and progression.

Authors:  Yasunori Iida; Baohui Xu; Haojun Xuan; Keith J Glover; Hiroki Tanaka; Xiaolei Hu; Naoki Fujimura; Wei Wang; Joshua R Schultz; Court R Turner; Ronald L Dalman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-01-03       Impact factor: 8.311

9.  Analysis of in situ and ex vivo vascular endothelial growth factor receptor expression during experimental aortic aneurysm progression.

Authors:  Maureen M Tedesco; Masahiro Terashima; Francis G Blankenberg; Zoia Levashova; Joshua M Spin; Marina V Backer; Joseph M Backer; Mien Sho; Eiketsu Sho; Michael V McConnell; Ronald L Dalman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-07-02       Impact factor: 8.311

10.  Angiotensin II infusion promotes ascending aortic aneurysms: attenuation by CCR2 deficiency in apoE-/- mice.

Authors:  Alan Daugherty; Debra L Rateri; Israel F Charo; A Phillip Owens; Deborah A Howatt; Lisa A Cassis
Journal:  Clin Sci (Lond)       Date:  2010-03-09       Impact factor: 6.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.